Clinical trials: Prostatic Disease
Benign Prostate Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia
- Trial name
- NCT02390882
- Testing
- HGP0412 capsule, HIP1402 capsule
- Where
- South Korea
- Volunteers
- 494 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Prostatic Neoplasms, Genital Neoplasms, Male
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
The study will consist of 2 parts: Part I (Dose Escalation) and Part II (Dose Expansion). In Part I, patients will participate in single, multiple, and long-term dosing periods using EPI-506 to determine safety, pharmacokinetics…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male, Prostatic Diseases
- Trial name
- NCT02606123
- Testing
- EPI-506
- Where
- 5 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- ESSA Pharmaceuticals
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).
- Trial name
- ENTHUSE M0 (NCT00626548)
- Testing
- ZD4054, Palcebo
- Where
- 322 sites in United States, Argentina and 37 more
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Benign Prostate Hyperplasia
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
Efficacy and Safety of Tamsulosin/Solifenacin Combination therapy in Patients with voiding symptoms and moderate to severe storage symptoms due to Benign Prostate Hyperplasia : a randomized, double blinded, parallel design…
- Trial name
- NCT02827578
- Testing
- Tamsulosin, Solifenacin
- Where
- South Korea
- Volunteers
- 588 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Hot Flashes, Prostate Cancer
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.
- Trial name
- NCT00005623
- Testing
- cyproterone acetate, quality-of-life assessment
- Where
- United States
- Sponsor
- Barr Laboratories
Prostate Cancer
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
The purpose of this study is to evaluate hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) against TAP-144-SR(3M) in prostate cancer patients previously treated with hormonal therapy.
- Trial name
- NCT01546623
- Testing
- TAP-144-SR(6M), TAP-144-SR(3M)
- Where
- 16 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Takeda
Prostatic Hyperplasia, Prostate
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
- Trial name
- PILUTS (NCT00547625)
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled.
- Trial name
- NCT00100243
- Testing
- Plenaxis
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Prostate Cancer, Prostate Cancer Metastatic Disease
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
The aim of this study is to assess the safety and dosimetry of [68Ga]Ga-OncoACP3 in patients with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, PSA Level Greater Than 0.2
- Trial name
- OncoACP-3 (NCT06840535)
- Testing
- [68Ga]Ga-OncoACP3
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Prostate Cancer
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone density, changes in blood…
- Trial name
- NCT01234350
- Where
- 160 sites in Belgium, Denmark and 13 more
- Volunteers
- 1,493 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia
A Study in Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured…
- Trial name
- NCT01152190
- Testing
- Tadalafil
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Metastatic Prostate Cancer
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
- Trial name
- PULSE (NCT07484269)
- Where
- Switzerland
- Volunteers
- 753 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
An open, multicenter and prospective study to evaluate the impact of the treatment with zoledronic acid 4 mg, on the quality of life and the skeletal-related events in patients with prostate cancer and bone metastasis that…
- Trial name
- NCT00237146
- Testing
- Zoledronic acid
- Where
- Venezuela
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
To identify the proportion of patients remaining medically castrated (testosterone level < 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.
- Trial name
- NCT00415246
- Testing
- Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)
- Where
- 31 sites in Belgium, France and 6 more
- Volunteers
- 100 people
- Sponsor
- Ipsen
Benign Prostatic Hyperplasia
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients.
- Trial name
- NCT03246880
- Testing
- Tamsulosin 0.2mg, Tadalafil 5mg
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Prostate Cancer
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
- Trial name
- NCT01317641
- Testing
- ODM-201
- Where
- 23 sites in United States, Czechia and 4 more
- Volunteers
- 136 people
- Sponsor
- Orion Corporation, Orion Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.